PMID- 26945339
OWN - NLM
STAT- MEDLINE
DCOM- 20170719
LR  - 20180814
IS  - 1532-0979 (Electronic)
IS  - 0147-5185 (Linking)
VI  - 40
IP  - 7
DP  - 2016 Jul
TI  - Incidental and Isolated Follicular Lymphoma In Situ and Mantle Cell Lymphoma In
      Situ Lack Clinical Significance.
PG  - 943-9
LID - 10.1097/PAS.0000000000000628 [doi]
AB  - Follicular lymphoma in situ (FLIS) and mantle cell lymphoma in situ (MCLIS) are
      histopathologic findings of undetermined clinical significance. We studied a
      series of 341 consecutive lymph node resection specimens from patients diagnosed 
      with colorectal (201 cases) and breast (140 cases) adenocarcinoma between 1998
      and 2000. Incidental and isolated FLIS was identified in 11/341 patients (3.23%),
      whereas incidental and isolated MCLIS was found in 2/341 patients (0.59%). None
      of these cases developed overt lymphoma. A second series of 17 cases of FLIS (16 
      cases) and MCLIS (1 case) from consultation files was analyzed. Five cases with
      incidental and isolated FLIS were identified. None of these cases developed overt
      lymphoma. Overall, none of the 16 cases with incidental and isolated FLIS in both
      series developed overt FL after a median follow-up of 54 months (range, 7 to 187 
      mo). However, 12 of these cases with a clinical suspicion of lymphoproliferative 
      disorder showed the association (in different lymph nodes) or combination (in the
      same sample) of FLIS or MCLIS with other lymphoid neoplasms (FL, splenic marginal
      zone lymphoma, nodal marginal zone lymphoma, Hodgkin lymphoma, diffuse large
      B-cell lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma,
      multiple myeloma). In conclusion, the clinical relevance of FLIS and MCLIS seems 
      to strictly depend on the clinical context. Incidental FLIS or MCLIS seem to have
      a very low risk for transformation, which recommends careful clinical examination
      after histopathologic diagnosis and conservative management with follow-up for a 
      limited period of time.
FAU - Bermudez, Glenda
AU  - Bermudez G
AD  - *Pathology and Haematology Departments double daggerBiobanco Valdecilla, Hospital
      Universitario Marques de Valdecilla, IDIVAL, Santander daggerPathology
      Department, Hospital Virgen de la Salud, Toledo, Spain.
FAU - Gonzalez de Villambrosia, Sonia
AU  - Gonzalez de Villambrosia S
FAU - Martinez-Lopez, Azahara
AU  - Martinez-Lopez A
FAU - Batlle, Ana
AU  - Batlle A
FAU - Revert-Arce, Jose B
AU  - Revert-Arce JB
FAU - Cereceda Company, Laura
AU  - Cereceda Company L
FAU - Ortega Bezanilla, Cesar
AU  - Ortega Bezanilla C
FAU - Piris, Miguel A
AU  - Piris MA
FAU - Montes-Moreno, Santiago
AU  - Montes-Moreno S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Surg Pathol
JT  - The American journal of surgical pathology
JID - 7707904
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Carcinoma in Situ/epidemiology/*pathology
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - *Incidental Findings
MH  - Lymph Nodes/pathology
MH  - Lymphoma, Follicular/epidemiology/*pathology
MH  - Lymphoma, Mantle-Cell/epidemiology/*pathology
MH  - Male
MH  - Middle Aged
MH  - Prevalence
EDAT- 2016/03/06 06:00
MHDA- 2017/07/20 06:00
CRDT- 2016/03/06 06:00
PHST- 2016/03/06 06:00 [entrez]
PHST- 2016/03/06 06:00 [pubmed]
PHST- 2017/07/20 06:00 [medline]
AID - 10.1097/PAS.0000000000000628 [doi]
PST - ppublish
SO  - Am J Surg Pathol. 2016 Jul;40(7):943-9. doi: 10.1097/PAS.0000000000000628.